Top Articles
FDA Replaces March 16 Serology COVID-19 Rules
Before issuing new guidance on May 4, the FDA okayed more than 200 tests, some were fraudulent
CEO SUMMARY: In the rush to allow companies and clinical laboratories to develop, validate, and bring to market serological tests for COVID-19, the federal Food and Drug Administration issued rules on March 16 that eased its requirements for these new assays. Because of the la...
COVID-19 Update Expert Offers Comments on FDA and Revised Serology Test Rules
Tougher rules issued on May 4 show FDA’s concern about faulty or fraudulent COVID-19 serological tests
CLINICAL LABORATORY DIRECTORS are asking what caused the federal Food and Drug Administration (FDA) to issue a highly questionable policy in March to allow serological tests for SARS-CoV-2 and then change that policy seven weeks later. Under a policy the agency issued March...
Legal Update New Lab Revenue Source: COVID-19 Worker Screening
CLINICAL LABORATORIES have a new revenue-generating opportunity, as some states relax stay-at-home rules: Many employers are likely to seek COVID-19 screening tests for employees returning to work to detect the presence of the new coronavirus. This new source of lab specimens and revenue gi...
California Research Team Analyzes Performance of 12 Serology Tests
Consistent method used to evaluate different serology tests
CEO SUMMARY: Researchers with the COVID-19 Testing Project used a multidisciplinary effort to analyze and compare the performance of 12 serological tests. One finding is that, 16 to 20 days or more after a confirmed infection with a molecular test, many of the 12 serological te...
To Stay Afloat, Dallas AP Group Cut Staff, Payroll
Early planning and federal funding also helped pathologists cut losses from COVID-19 pandemic
CEO SUMMARY: As early cases of COVID-19 spread in some states, pathologists at the 50-member ProPath group in Dallas prepared for a widespread outbreak by preserving cash and working with bankers and other advisors to apply for federal stimulus funding. Executives also fur...
Helping Labs with Cash Flow, COVID-19 Response
ROUTINE SPECIMEN VOLUME REMAINS DOWN by 50% or more for clinical laboratories and anatomic pathology groups in the United States because of the pandemic. Through the end of last week, The Dark Report estimates that labs in the U.S. have lost almost $7 billion since the first week of March. That’s when patients stopped visiting their doctors and hospitals ce...
Don’t Be at the Mercy of the Tumultuous Healthcare Revolution
Subscribe to The Dark Report for as little as $15.27 per week.
Get the most expert business intelligence for clinical laboratories and pathology groups available today. Subscribe to The Dark Report.
CURRENT ISSUE
Volume XXVII No. 7 – May 11, 2020
LABS CAN REST EASIER knowing that the initial flood of unvalidated faulty or fraudulent serological COVID-19 tests is being halted now that the FDA has done an about-face on its policies. And THE DARK REPORT offers behind-the-scenes insights into the COVID-19 Testing Project which used a multidisciplinary effort to analyze and compare the performance of 12 of these tests. In other good news, THE DARK REPORT reports on a potential new revenue source for cash-strapped labs.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Need A Group Membership? Company Discounts are Available!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
